Beneficial Effect of Carbohydrate Maldigestion Induced by a Disaccharidase Inhibitor (AO-128) in the Treatment of Chronic Portal-Systemic Encephalopathy: A Double-Blind, Randomized, Controlled Trial

Abstract

Background: The most widely used treatment of portal-systemic encephalopathy (PSE) is the administration of oral, non-absorbable disaccharides. Theoretically, the inhibition of intestinal disaccharidases should induce malabsorption of disaccharides and increase delivery of undigested carbohydrates to the colon, thus stimulating the effects of lactulose and other non-absorbable disaccharides (that is, lactitol and lactose). AO-128 is an N-substituted derivative of valeolamine, an aminocyclitol that selectively inhibits intestinal disaccharidases. This study was performed to investigate whether AO-128 could be used as adjuvant therapy for the treatment of mild PSE in cirrhotic patients. Methods: